Cargando…

Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer

Goserelin is an effective alternative to surgery or estrogen therapy in prostate cancer palliation, and possibly to ovariectomy in premenopausal breast cancer. However, not all users of goserelin can benefit from it, or some patients are not sensitive to goserelin. The advent of network pharmacology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yue, Sun, Huimin, Zheng, Jianzhong, Shao, Chen, Zhang, Dongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788753/ https://www.ncbi.nlm.nih.gov/pubmed/33407865 http://dx.doi.org/10.1186/s13578-020-00517-w

Ejemplares similares

Update on the management of prostate cancer with goserelin acetate: patient perspectives
por: Wilson, Shandra
Publicado: (2009)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

Primary Mediastinal Choriocarcinoma in an Elderly Patient with Concurrent Goserelin-Treated Prostate Adenocarcinoma
por: Røge, Rasmus, et al.
Publicado: (2019)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
por: Abdel Azim, Hamdy, et al.
Publicado: (2018)

No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro
por: Hermann, Robert M, et al.
Publicado: (2007)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature
por: Mahadevan, Aditya, et al.
Publicado: (2023)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial
por: Abo El-Enen, Mohamed, et al.
Publicado: (2016)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
por: Jiang, Hang, et al.
Publicado: (2014)

Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature
por: Yang, Jia-Wen, et al.
Publicado: (2021)

Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats
por: Yutong, Mao, et al.
Publicado: (2023)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Both Castration and Goserelin Acetate Ameliorate Myocardial Ischemia Reperfusion Injury and Apoptosis in Male Rats
por: Hadi, Najah R., et al.
Publicado: (2014)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial
por: Gu, Chengyuan, et al.
Publicado: (2023)

Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
por: Aljabri, Belal, et al.
Publicado: (2021)

Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer
por: Noguchi, Shinzaburo, et al.
Publicado: (2015)

Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway
por: Zhang, Ning, et al.
Publicado: (2018)

Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems
por: Shao, Huimin, et al.
Publicado: (2022)

Identification of pathologically insignificant prostate cancer is not accurate in unscreened men
por: Shaw, G L, et al.
Publicado: (2014)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_172e8k526u7ae30dpg2glv8gpj